J. D’souza

发表

Oxcarbazepine: double-blind, randomized, placebo-control, monotherapy trial for partial seizures.

R. Fisher, S. Schachter, K. Laxer, 1999, Neurology.

Oxcarbazepine (Trileptal) as monotherapy in patients with partial seizures

S. Schachter, A. Beydoun, B. Vazquez, 2001, Neurology.

Adjunctive therapy with oxcarbazepine in children with partial seizures

S. Weinstein, D. Mandelbaum, D. Bettis, 2000, Neurology.

Pharmacokinetic drug interactions in children taking oxcarbazepine

S. Milosavljev, W. Sallas, J. D’souza, 2003, Clinical pharmacology and therapeutics.

Oxcarbazepine Pharmacokinetics and Tolerability in Children With Inadequately Controlled Epilepsy

O. Dulac, C. Bulteau, J. Motte, 2004, Journal of clinical pharmacology.

Oxcarbazepine in migraine headache

S. Silberstein, J. Saper, J. D’souza, 2008, Neurology.

Correlations of plasma and urinary phenylacetic acid and phenylethylamine concentrations with eating behavior and mood rating scores in brofaromine-treated women with bulimia nervosa.

S. Kennedy, D. Goldbloom, A. Boulton, 1994, Journal of psychiatry & neuroscience : JPN.

Is there a role for selective monoamine oxidase inhibitor therapy in bulimia nervosa? A placebo-controlled trial of brofaromine.

S. Kennedy, C. Davis, D. Goldbloom, 1993, Journal of clinical psychopharmacology.

Sustained Efficacy and Long‐term Safety of Oxcarbazepine: One‐year Open‐label Extension of a Study in Refractory Partial Epilepsy

A. Beydoun, R. Sachdeo, E. Kutluay, 2003, Epilepsia.

Clinical features associated with placebo response in refractory focal epilepsy

K. Stavem, S. Beyenburg, D. Schmidt, 2013, Epilepsy & Behavior.

Effects of chronic brofaromine administration on biogenic amines including sulphatoxymelatonin and acid metabolites in patients with bulimia nervosa

S. Kennedy, Gregory M. Brown, J. D’souza, 1993, Neurochemical Research.

A cost comparison of alternative regimens for treatment-refractory partial seizure disorder: an econometric analysis.

C. Pashos, Qin Wang, S. Arcona, 2005, Clinical therapeutics.

Reversible monoamine oxidase-A inhibitors in panic disorder.

R. Bowen, D. Bakish, J. D’souza, 1993, Clinical neuropharmacology.

BROFAROMINE AND CLOMIPRAMINE IN PANIC DISORDER: A DOUBLE‐BLIND STUDY.

R. Bowen, D. Bakish, J. D’souza, 1992 .

Efficacy, safety, and tolerability of oxcarbazepine monotherapy

G. Barkley, Walter Martínez, J. D’souza, 2006, Epilepsy & Behavior.

Long-term safety and tolerability of oxcarbazepine in children: A review of clinical experience

B. Bourgeois, J. D’souza, 2005, Epilepsy & Behavior.

Effects of oxcarbazepine on sodium concentration and water handling

R. Sachdeo, P. Mesenbrink, J. D’souza, 2002, Annals of neurology.

Oxcarbazepine Placebo‐Controlled, Dose‐Ranging Trial in Refractory Partial Epilepsy

C. Elger, H. Stefan, A. Scaramelli, 2000, Epilepsia.

Oxcarbazepine monotherapy for partial-onset seizures

A. Beydoun, G. Krauss, W. Rosenfeld, 2000, Neurology.

An open-label, prospective, exploratory study of patients with epilepsy switching from levetiracetam to brivaracetam

S. Borghs, Stephen L. Yates, T. Fakhoury, 2015, Epilepsy & Behavior.

Oxcarbazepine Placebo‐Controlled, Dose‐Ranging Trial in Refractory Partial Epilepsy

C. Elger, H. Stefan, A. Scaramelli, 2000 .

Safety and tolerability of oxcarbazepine in elderly patients with epilepsy

A. Beydoun, E. Kutluay, J. D’souza, 2003, Epilepsy & Behavior.

The effect of the mao-a selective inhibitor brofaromine on the plasma and urine concentrations of some biogenic amines and their acidic metabolites in bulimia nervosa

S. Kennedy, D. Goldbloom, A. Boulton, 1993, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

A double-blind, randomized, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents.

T. Wilens, R. Findling, R. Kowatch, 2006, The American journal of psychiatry.

Evaluation of brivaracetam efficacy as monotherapy in adult patients with focal seizures

J. Wade, R. Schoemaker, A. Stockis, 2017, Epilepsy Research.

Treatment of idiopathic generalized epilepsy – a review of the evidence

A. Beydoun, J. D’souza, 2012, Expert opinion on pharmacotherapy.

Reduction of aspirin-induced fecal blood loss with low-dose misoprostol tablets in man

Max M. Cohen, J. D’souza, Lynn Armstrong, 1985, Digestive Diseases and Sciences.

Major malformations in offspring of women with epilepsy.

R. Zaninelli, J. D’souza, Michael I. Miller, 2003, Neurology.

Lacosamide: pharmacology, mechanisms of action and pooled efficacy and safety data in partial-onset seizures

A. Beydoun, J. D’souza, David Hébert, 2009, Expert review of neurotherapeutics.

Patient and physician perceptions of disease management in Parkinson’s disease: results from a US-based multicenter survey

N. Hermanowicz, J. D’souza, J. Fishman, 2019, Neuropsychiatric disease and treatment.

Tolerability, safety, and efficacy of adjunctive brivaracetam for focal seizures in older patients: A pooled analysis from three phase III studies

M. Brodie, J. D’souza, J. Whitesides, 2016, Epilepsy Research.

Dr. Wagner and colleagues reply [8]

T. Wilens, R. Findling, R. Kowatch, 2006 .